Related Experiment Video
Updated: Feb 2, 2026

ATAC-Seq Optimization for Cancer Epigenetics Research
Published on: June 30, 2022
Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors
Zhenghui Liu1, Yingxue Gao1, Xiong Li1
1a Xiangya Hospital, Central South University , Changsha , Hunan , China.
Abstract:
Introduction: Epigenetic modification without DNA sequence mutation plays an important role in cancer development. Some small molecular inhibitors targeting key epigenetic molecules have been approved by the Food and Drug Administration to treat hematological malignancies. However, the anticancer effects of these drugs on solid tumors are not satisfactory, and the mechanisms of action remain largely unknown. Areas covered: The review summarizes the latest research on cancer epigenetics and discusses the potentials and limitations of using epigenetic drugs to treat solid tumors. An analysis of possible reasons for epigenetic drug treatment failure in solid tumors in some clinical trials is discussed along with prospects for future development. Expert commentary: Next-generation small molecule inhibitors will target novel epigenetic regulators with high cancer specificity. Combined modalities exploiting epigenetic drugs with chemo-/radiotherapy, molecular-targeting drugs, and immunotherapy will be able to effectively treat solid tumors in the near future.
Insights
Epigenetic drugs show promise for cancer treatment, but their effectiveness in solid tumors is limited. Future strategies involve next-generation inhibitors and combination therapies for improved outcomes.
Area of Science:
- Oncology
- Epigenetics
- Pharmacology
Background:
- Epigenetic modifications, crucial in cancer development, are targeted by approved drugs for hematological malignancies.
- Current epigenetic drugs show limited efficacy in solid tumors, with mechanisms often unclear.
Purpose of the Study:
- To review current research on cancer epigenetics.
- To discuss the potential and limitations of epigenetic drugs for solid tumors.
- To analyze reasons for treatment failures and explore future development.
Main Methods:
- Literature review of recent studies on cancer epigenetics.
- Analysis of clinical trial data for epigenetic drug efficacy in solid tumors.
- Discussion of emerging therapeutic strategies.
Main Results:
- Epigenetic drugs have shown success in blood cancers but not solid tumors.
- Understanding the mechanisms of action and resistance is critical for solid tumor treatment.
- Combination therapies and novel drug development are key.
Conclusions:
- Next-generation epigenetic inhibitors targeting novel regulators offer improved specificity.
- Combining epigenetic drugs with chemotherapy, radiotherapy, targeted therapy, or immunotherapy holds promise for treating solid tumors.
More Related Videos
10:26Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
08:34An Engineered Split-TET2 Enzyme for Chemical-inducible DNA Hydroxymethylation and Epigenetic Remodeling
Published on: December 18, 2017
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...